LLukas22/scidocs huggingface dataset:
Design of Orthogonal MIMO Handset Antennas Based on Characteristic Mode Manipulation at Frequency Bands Below 1 GHz

Multi-antenna design in compact mobile handsets at frequency bands below 1 GHz is very challenging, since severe mutual coupling is commonly induced by simultaneous excitation of the chassis' fundamental dipole mode by more than one antenna element. To address this problem, a novel multi-antenna design approach is proposed herein to obtain efficient and uncorrelated antennas. By manipulating the chassis structure, more than one characteristic mode is enabled to resonate at frequencies below 1 GHz. With proper excitations for different characteristic modes, which are orthogonal to each other, well matched multi-antennas with low coupling and correlation are achieved. A chassis loaded with two T-shaped metal strips above its longer edges is taken as an example modification to illustrate the effectiveness of the proposed design approach at 900 MHz. This modification creates a new characteristic mode which resonates near 900 MHz. Afterward, two antenna feeds were designed to efficiently excite the chassis' fundamental dipole mode and the T-strip mode with very low correlation. The T-strip antenna covers LTE Band 8 (880-960 MHz), and the dipole mode antenna covers both LTE Band 5 (824-894 MHz) and LTE Band 8. The proposed dual-antenna design was found to outperform a reference design significantly, both with and without user interactions (i.e., one-hand and two-hand data grips). Practical aspects of mobile handset antennas are also investigated. The prototype was also fabricated and measured, and the measured results show reasonable agreements with the simulated results.
Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study

BACKGROUND
This study examined the effects of lisdexamfetamine dimesylate (LDX) on quality of life (QOL) in adults with attention-deficit/hyperactivity disorder (ADHD) and clinically significant executive function deficits (EFD).


METHODS
This report highlights QOL findings from a 10-week randomized placebo-controlled trial of LDX (30-70 mg/d) in adults (18-55 years) with ADHD and EFD (Behavior Rating Inventory of EF-Adult, Global Executive Composite [BRIEF-A GEC] ≥65). The primary efficacy measure was the self-reported BRIEF-A; a key secondary measure was self-reported QOL on the Adult ADHD Impact Module (AIM-A). The clinician-completed ADHD Rating Scale version IV (ADHD-RS-IV) with adult prompts and Clinical Global Impressions-Severity (CGI-S) were also employed. The Adult ADHD QoL (AAQoL) was added while the study was in progress. A post hoc analysis examined the subgroup having evaluable results from both AIM-A and AAQoL.


RESULTS
Of 161 randomized (placebo, 81; LDX, 80), 159 were included in the safety population. LDX improved AIM-A multi-item domain scores versus placebo; LS mean difference for Performance and Daily Functioning was 21.6 (ES, 0.93, P<.0001); Impact of Symptoms: Daily Interference was 14.9 (ES, 0.62, P<.0001); Impact of Symptoms: Bother/Concern was 13.5 (ES, 0.57, P=.0003); Relationships/Communication was 7.8 (ES, 0.31, P=.0302); Living With ADHD was 9.1 (ES, 0.79, P<.0001); and General Well-Being was 10.8 (ES, 0.70, P<.0001). AAQoL LS mean difference for total score was 21.0; for subscale: Life Productivity was 21.0; Psychological Health was 12.1; Life Outlook was 12.5; and Relationships was 7.3. In a post hoc analysis of participants with both AIM-A and AAQoL scores, AIM-A multi-item subgroup analysis scores numerically improved with LDX, with smaller difference for Impact of Symptoms: Daily Interference. The safety profile of LDX was consistent with amphetamine use in previous studies.


CONCLUSIONS
Overall, adults with ADHD/EFD exhibited self-reported improvement on QOL, using the AIM-A and AAQoL scales in line with medium/large ES; these improvements were paralleled by improvements in EF and ADHD symptoms. The safety profile of LDX was similar to previous studies.


TRIAL REGISTRATION
ClinicalTrials.gov, NCT01101022.
3D printing bone models extracted from medical imaging data

Additive manufacturing in the form of 3D printing is becoming more common with the rise of low-cost hobby machines which makes research in the field of medicine more accessible. This article explores and experiments with methods of producing three dimensional replicas of body parts as education material from the medical imaging data of Computed Tomography and Magnetic Resonance Imaging.
Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).

BACKGROUND
The implantable cardioverter defibrillator (ICD) is superior to amiodarone for secondary prophylaxis of sudden cardiac death. However, the magnitude of this benefit over long-term follow-up is not known. Thus, our objective was to evaluate the long-term consequences of using amiodarone versus an ICD as first-line monotherapy in patients with a prior history of sustained ventricular tachycardia/ventricular fibrillation or cardiac arrest.


METHODS AND RESULTS
A total of 120 patients were enrolled at St Michael's Hospital in the Canadian Implantable Defibrillator Study (CIDS) and were randomly assigned to receive either amiodarone (n=60) or an ICD (n=60). The treatment strategy was not altered after the end of CIDS unless the initial assigned therapy was not effective or was associated with serious side effects. After a mean follow-up of 5.6+/-2.6 years, there were 28 deaths (47%) in the amiodarone group, compared with 16 deaths (27%) in the ICD group (P=0.0213). Total mortality was 5.5% per year in the amiodarone group versus 2.8% per year in the ICD group (hazard ratio of amiodarone: ICD, 2.011; 95% confidence interval, 1.087 to 3.721; P=0.0261). In the amiodarone group, 49 patients (82% of all patients) had side effects related to amiodarone, of which 30 patients (50% of all patients) required discontinuation or dose reduction; 19 patients crossed over to ICD because of amiodarone failure (n=7) or side effects (n=12).


CONCLUSIONS
In a subset of CIDS, the benefit of the ICD over amiodarone increases with time; most amiodarone-treated patients eventually develop side effects, have arrhythmia recurrences, or die.
Development and validation of the Alcohol Identity Implicit Associations Test (AI-IAT).

Alcohol identity is the extent to which an individual perceives drinking alcohol to be a defining characteristic of his or her self-identity. Although alcohol identity might play an important role in risky college drinking practices, there is currently no easily administered, implicit measure of this concept. Therefore we developed a computerized implicit measure of alcohol identity (the Alcohol Identity Implicit Associations Test; AI-IAT) and assessed its reliability and predictive validity in relation to risky college drinking practices. One hundred forty-one college students completed the AI-IAT. Again 3- and 6-months later, we administered the AI-IAT and indices of engagement in risky college drinking practices. A subset of participants also completed the previously-validated implicit measure of alcohol identity. Scores on the AI-IAT were stable over time, internally consistent, and positively correlated with the previously-validated measure of alcohol identity. Baseline AI-IAT scores predicted future engagement in risky college drinking practices, even after controlling for standard alcohol consumption measures. We conclude that the AI-IAT reliably measures alcohol identity, a concept that appears to play an important role in risky college drinking practices.
Optimized Reversible Multiplier Circuit

Reversible logic circuits have received significant attention in quantum computing, low power CMOS design, optical information processing, DNA computing, bioinformatics, and nanotechnology. This paper presents two new 4× 4 bit reversible multiplier designs which have lower hardware complexity, less garbage bits, less quantum cost and less constant inputs than previous ones, and can be generalized to construct efficient reversible n×n bit multipliers. An implementation of reversible HNG is also presented. This implementation shows that the full adder design using HNG is one of the best designs in term of quantum cost. An implementation of MKG is also presented in order to have a fair comparison between our proposed reversible multiplier designs and the existing counterparts. The proposed reversible multipliers are optimized in terms of quantum cost, number of constant inputs, number of garbage outputs and hardware complexity. They can be used to construct more complex systems in nanotechnology.
Wideband power amplifier MMICs utilizing GaN on SiC

The application of GaN on SiC technology to wideband power amplifier MMICs is explored. The unique characteristics of GaN on SiC applied to reactively matched and distributed wideband circuit topologies are discussed, including comparison to GaAs technology. A 2 – 18 GHz 11W power amplifier MMIC is presented as an example.
Patterns of Admixture and Population Structure in Native Populations of Northwest North America

The initial contact of European populations with indigenous populations of the Americas produced diverse admixture processes across North, Central, and South America. Recent studies have examined the genetic structure of indigenous populations of Latin America and the Caribbean and their admixed descendants, reporting on the genomic impact of the history of admixture with colonizing populations of European and African ancestry. However, relatively little genomic research has been conducted on admixture in indigenous North American populations. In this study, we analyze genomic data at 475,109 single-nucleotide polymorphisms sampled in indigenous peoples of the Pacific Northwest in British Columbia and Southeast Alaska, populations with a well-documented history of contact with European and Asian traders, fishermen, and contract laborers. We find that the indigenous populations of the Pacific Northwest have higher gene diversity than Latin American indigenous populations. Among the Pacific Northwest populations, interior groups provide more evidence for East Asian admixture, whereas coastal groups have higher levels of European admixture. In contrast with many Latin American indigenous populations, the variance of admixture is high in each of the Pacific Northwest indigenous populations, as expected for recent and ongoing admixture processes. The results reveal some similarities but notable differences between admixture patterns in the Pacific Northwest and those in Latin America, contributing to a more detailed understanding of the genomic consequences of European colonization events throughout the Americas.
A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.

BACKGROUND
Vernakalant, a relatively atrial-selective antiarrhythmic drug, has previously demonstrated efficacy for the acute conversion of atrial fibrillation (AF) to sinus rhythm. This study was designed to determine the most appropriate oral dose of vernakalant for the prevention of AF recurrence postcardioversion.


METHODS AND RESULTS
Patients with nonpermanent AF were randomized to 150, 300, or 500 mg vernakalant or placebo twice daily for up to 90 days. The efficacy analysis was conducted on 605 of 735 patients who entered the maintenance phase on day 3 after cardioversion. The time to the first recurrence of symptomatic sustained AF was significantly longer in the 500 mg vernakalant group, with a median of >90 days versus 29 days in the placebo group (hazard ratio, 0.735; P=0.0275). No significant effect was seen at the lower doses. The percent of patients in sinus rhythm at day 90 was 41%, 39%, and 49% in the 150-mg (n=147), 300-mg (n=148), and 500-mg (n=150) vernakalant groups, respectively, compared with 36% in the placebo group (n=160). There were no vernakalant-related proarrhythmic events. Related serious adverse events occurred in 2 patients in the 150-mg vernakalant group and in 1 patient in each of the other groups.


CONCLUSIONS
Vernakalant, 500 mg twice daily, appears to be effective and safe for the prevention of AF recurrence after cardioversion. The absence of proarrhythmia and favorable safety profile is an important finding for the drug.


CLINICAL TRIAL REGISTRATION
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00526136.
Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.

SUMMARY
The objectives of this study were to identify the factors influencing antihypertensive response to the angiotensin receptor blocker, olmesartan medoxomil, or the calcium channel blocker, azelnidipine, and to discuss the possibility of utilizing them as predictors for drug selection prior to therapy. A two-way crossover study of olmesartan medoxomil and azelnidipine was conducted in 29 patients with mild to moderate essential hypertension. The 24-hour ambulatory blood pressure measurements (ABPM) and plasma drug concentrations were obtained on the first and at the end of each treatment period, and were analyzed using population pharmacokinetic/pharmacodynamic (PK/PD) modeling approach. The population PK/PD models considering circadian variations in baseline blood pressure well described the observed plasma drug concentrations and 24-hour ABPM profiles. Pre-treatment plasma renin activity (PRA) was identified as a significant covariate on the maximum drug effect (E(max)) of olmesartan, whereas azelnidpine E(max) was independent of patient background characteristics investigated. No patient was found to have a high E(max) to one agent who also had a high E(max) to the other. In conclusion, the effects of olmesartan medoxomil and azelnidipine were modestly correlated with pharmacokinetic profiles, and the pre-treatment PRA level could be a useful determinant of responsiveness in selecting olmesartan medoxomil and azelnidipine.
The role of hyaluronic acid fillers (Restylane) in facial cosmetic surgery: review and technical considerations.

BACKGROUND
Bioengineered hyaluronic acid derivatives are currently available that provide for safe and effective soft-tissue augmentation in the comprehensive approach to nonsurgical facial rejuvenation. Current hyaluronic acid fillers do not require preinjection skin testing and produce reproducible, longer-lasting, nonpermanent results compared with other fillers, such as collagen.


METHODS
A review of the authors' extensive experience at the University of Texas Southwestern Medical Center was conducted to formulate the salient requirements for successful utilization of hyaluronic acid fillers. Indications, technical refinements, and key components for optimized product administration categorized by anatomical location are described. The efficacy and longevity of results are also discussed.


RESULTS
Bioengineered hyaluronic acid fillers allow for safe and effective augmentation of selected anatomical regions of the face, when properly administered. Combined treatment with botulinum toxin type A can enhance the effects and longevity by as much as 50 percent. Key components to optimal filler administration include proper anatomical evaluation, changing or combining various fillers based on particle size, altering the depth of injection, using different injection techniques, and coadministration of botulinum toxin type A when indicated. Concomitant administration of hyaluronic acid fillers along with surgical methods of facial rejuvenation can serve as a powerful tool in maximizing a comprehensive treatment plan.


CONCLUSIONS
Current techniques in nonsurgical facial rejuvenation and shaping with hyaluronic acid fillers are safe, effective, and long-lasting. Combination regimens that include surgical facial rejuvenation techniques and/or coadministration of botulinum toxin type A further optimize results, leading to greater patient satisfaction.
Some Asymptotic Bijections

Abstract The notion of an asymptotic bijection is introduced and used to give bijective proofs of infinite summation formulas for set partitions (Dobinski's formula) and involutions.
Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

OBJECTIVES
Antiretroviral therapy during pregnancy is recommended to reduce the risk of mother-to-child transmission of HIV and for maternal care management. Physiological changes during pregnancy can affect pharmacokinetics, potentially altering pharmacological activity. We therefore evaluated the pharmacokinetics of twice-daily (bid) darunavir in HIV-1-infected pregnant women.


METHODS
HIV-1-infected pregnant women receiving an antiretroviral regimen containing darunavir/ritonavir 600/100 mg bid were enrolled in this study. Total and unbound darunavir and total ritonavir plasma concentrations were obtained over 12 h during the second and third trimesters and postpartum. Total darunavir and ritonavir plasma concentrations were determined using a validated high-performance liquid chromatography tandem mass spectrometry assay and unbound darunavir was determined using (14) C-darunavir-fortified plasma. Pharmacokinetic parameters were derived using noncompartmental analysis.


RESULTS
Data were available for 14 women. The area under the plasma concentration-time curve from 0 to 12 h (AUC12h) for total darunavir was 17-24% lower during pregnancy than postpartum. The AUC12h for unbound darunavir was minimally reduced during pregnancy vs. postpartum. The minimum plasma concentration (Cmin) of total and unbound darunavir was on average 43-86% and 10-14% higher, respectively, during pregnancy vs. postpartum. The antiviral response (< 50 HIV-1 RNA copies/mL) was 33% at baseline and increased to 73-90% during treatment; the percentage CD4 count increased over time. One serious adverse event was reported (increased transaminase). All 12 infants born to women remaining in the study at delivery were HIV-1-negative; four of these infants were premature.


CONCLUSIONS
Total darunavir exposure decreased during pregnancy. No clinically relevant change in unbound (active) darunavir occurred during pregnancy, suggesting that no dose adjustment is required for darunavir/ritonavir 600/100 mg bid in pregnant women.
A Look at Parsing and Its Applications

This paper provides a brief introduction to recent work in st atistical parsing and its applications. We highlight succes ses to date, remaining challenges, and promising future work.
Numerical integration using sparse grids

We present new and review existing algorithms for the numerical integration of multivariate functions defined over d-dimensional cubes using several variants of the sparse grid method first introduced by Smolyak [49]. In this approach, multivariate quadrature formulas are constructed using combinations of tensor products of suitable one-dimensional formulas. The computing cost is almost independent of the dimension of the problem if the function under consideration has bounded mixed derivatives. We suggest the usage of extended Gauss (Patterson) quadrature formulas as the one‐dimensional basis of the construction and show their superiority in comparison to previously used sparse grid approaches based on the trapezoidal, Clenshaw–Curtis and Gauss rules in several numerical experiments and applications. For the computation of path integrals further improvements can be obtained by combining generalized Smolyak quadrature with the Brownian bridge construction.
Long term effects of intra-articular botulinum toxin a for refractory joint pain

The purpose of this case series review is to describe our 12 month clinical experience with intra-articular injections of Botulinum toxin Type A (BoNT/A) for refractory joint pain. Eleven patients with chronic arthritis who had failed treatment with oral and/or intra-articular medications and were not surgical candidates were referred to us for management of moderate to severe refractory joint pain in 15 joints. The use of BoNT/A to treat joint pain is a non-FDA approved “off label” treatment with potential side effects. After a detailed explanation of the joint injection procedure, signed informed consent was obtained for the procedure. Fifteen joints were injected with BoNT/A (Allergan, Inc): six lower extremity joints (3 knees, 3 ankles) with 25-50 units and nine shoulders with 50-100 units. Patients were followed for one year or longer. Maximum relief of pain was measured by comparing baseline pain on a numeric rating scale (0-10) to pain at the time of maximum relief (paired t-test). Maximum improvement in function was assessed using paired t-tests for improvement in active flexion and abduction for the shoulder joint, and by the time to perform sit to stand ten times (the timed stands test, TST) for the lower extremity joints. Results: Two patients were female and nine were male, aged 42-82 years. Five had osteoarthritis (OA), five had rheumatoid arthritis (RA) and one had psoriatic arthritis. All patients were on analgesic and/or anti-inflammatory medications and all joints had previous intra-articular steroid or viscosupplement injections with inadequate or unsatisfactory benefit. A clinically and statistically significant improvement was noted after IA-BoNT/ A injections. The mean maximum decrease in lower extremity joint pain was 55% (p =0.02) and the 36% (p =0.044) improvement in the Timed Stands Test was noted at four to ten weeks after injection. There was a 71% mean maximum reduction in shoulder pain severity from 8.2 ± 1.1 to 2.4 ± 1.9 (p <0.001). Active range of motion increased 67% in flexion (from 67.8 ± 27.6 to 113.3 ± 46.6 degrees, p =0.001) and 42% in abduction (from 50 18.5 degrees to 71.1 ± 23.1 degrees p =0.01). No immediate or delayed adverse effects related to BoNT/A were noted after the injection. Duration of pain relief was variable and ranged from 3 to 12 months. Five joints were re-injected with IA-BoNT/A and had a similar decrease in joint pain that lasted 3 to 12 months. Conclusions: This is the first report of the long term effects of intra-articular BoNT/A injections to treat chronic joint pain and the efficacy of repeated injections. Although this study was small, and uncontrolled the results suggest that IA-BoNT/ A injections are an effective and safe treatment for chronic joint pain disorders.